University of California San Francisco

Johannes Kratz MD
Johannes
Kratz
MD

Associate Professor of Surgery
Interim Chief of Thoracic Surgery
Division of Cardiothoracic Surgery
Van Auken Endowed Chair in Thoracic Oncology
Director, Minimally Invasive and Robotic Thoracic Surgery
Director, Thoracic Surgery Residency Program
Medical Director of Robotic Surgery, UCSF Health
 

UCSF Diversity, Equity, and Inclusion Champion badge

Academic Office:
500 Parnassus Ave, MUW 405, Box 0118
San Francisco, CA 94143-0118
Tel: (415) 353-8890
Email: [email protected]   
Admin: [email protected] 

Thoracic Surgery & Oncology Program 
1600 Divisadero St., 4th Floor, Box 1705
San Francisco, CA 94115
Tel: 415-885-3882

Biography

Johannes R. Kratz, M.D. is Medical Director of Robotic Surgery at UCSF and the Director of Minimally Invasive and Robotic Thoracic Surgery. Kratz graduated magna cum laude from Harvard Medical School and holds a Masters in Philosophy from Stanford.

Kratz worked as research fellow in the Thoracic Oncology Lab from 2008-2011 where he played a pivotal role in the development of a prognostic assay for early-stage lung cancer patients. The novel assay was validated in an international clinical trial led by thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D. The assay better predicted risk of death in early-stage lung cancer patients versus conventional staging guidelines and later successfully identified Stage 1A lung cancer patients who had a very high likelihood of mortality after surgery. Kratz finished his clinical training as a clinical fellow in Thoracic Surgery at UCSF from 2014 - 2017 and subsequently joined the faculty.

Kratz holds the Van Auken Endowed Chair in Thoracic Oncology. He has been the recipient of numerous awards and honors including the UCSF Health Exceptional Physician Award, Hellman Family Clinical-Translational Research Development Award, Michael DeBakey Research Scholarship, Cardiothoracic Surgery Faculty Teaching Award, Haile T. Debas Academy of Medical Educators Excellence in Teaching Award, Partners Healthcare Teaching Award, Willard M. Daggett Award, Edward Churchill Surgical Research Fellowship, Wyeth Scholarship of the American College of Surgeons, John E. Thayer Scholarship Award, Howard Hughes Medical Fellows Program Continued Support Award, and designation as a Soma Weiss Scholar.

Awards & Honors

Award Conferred By Date
Haile T. Debas Academy of Medical Educators Excellence in Teaching Award University of California, San Francisco 2023
Cardiothoracic Surgery Faculty Teaching Award University of California, San Francisco 2021
Michael DeBakey Research Scholarship American Association for Thoracic Surgery 2019
Hellman Family Clinical-Translational Research Development Award Bakar ImmunoX Initiative 2019
Haile T. Debas Academy of Medical Educators Excellence in Teaching Award University of California, San Francisco 2019
Van Auken Endowed Chair in Thoracic Oncology University of California, San Francisco 2018
UCSF Health Exceptional Physician Award University of California, San Francisco 2017
First Place, Oral Presentation, Harvard Medical School Surgery Research Conference Harvard Medical School 2012
Partners HealthCare Resident/Fellow as Teacher Award Partners HealthCare 2012
President's Conference Selection, World Conference on Lung Cancer International Association for the Study of Lung Cancer 2011
Willard M. Daggett Award Massachusetts General Hospital 2010
Wyeth Scholarship of the American College of Surgeons for the Study of Inflammation Massachusetts General Hospital 2008
Aesculapian Club Harvard Medical School 2006
John E. Thayer Scholarship Award Harvard Medical School 2006
Soma Weiss Scholar Award Harvard Medical School 2005
Howard Hughes Research Training Fellowship Harvard Medical School 2004

Education

Institution Degree Dept or School End Date
University of California Diversity, Equity, and Inclusion Champion Training 2019
University of California Fellowship Cardiothoracic Surgery 2017
Massachusetts General Hospital Residency General Surgery 2014
Harvard Medical School M.D. (Magna Cum Laude) 2006
Stanford University M.A. Philosophy 2000
Stanford University B.S. (with Honors with Distinction) Biological Sciences 1999
Stanford University B.A. (with Distinction) Philosophy 1999

Board Certifications

American Board of Surgery

American Board of Thoracic Surgery

Clinical Expertise

Carcinoid Tumors
Chest Wall Tumors
Lung Transplantation
Malignant Mesothelioma
Mediastinal Masses
Minimally Invasive Thoracic Surgery
Non-Small Cell Lung Cancer
Robotic Thoracic Surgery
Small Cell Lung Cancer
Thymoma & Thymic Carcinoma
Tracheal Tumors
Video-Assisted Thoracoscopic Surgery (VATS)

Clinical Trials

  1. Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial (NCT03508830)
    Related Conditions: Postoperative Pain, Opioid Use| Start Date: | End Date:

Grants and Funding

  • Immune Phenotypes of High-Risk Early Stage Lung Adenocarcinoma | American Association of Thoracic Surgery | 2020-07-01 - 2022-06-30 | Role: Principal Investigator
  • CoProject Pilot in Early-Stage Lung Cancer | Bakar ImmunoX Foundation | 2019-08-01 - 2021-07-31 | Role: Principal Investigator
  • COVID-19 Related Rapid Research Pilot Initiative | University of California, San Francisco | 2020-06-03 - 2021-06-02 | Role: Principal Investigator
  • Lung Cancer Tumor Immune Microenvironments | Helen Diller Family Comprehensive Cancer Center | 2019-10-19 - 2020-09-30 | Role: Principal Investigator

Research Narrative

The Kratz lab focuses on the genetic and immunological mechanisms that drive early-stage, surgically resectable thoracic malignancies. These malignancies include lung cancer, esophageal cancer, and thymic cancer. The lab uses novel high-throughput “-omics” techniques such as genomic DNA and RNA sequencing, proteomics, and metabolomics to unravel the complex nature of early-stage thoracic malignancies. At the same time, the lab actively investigates the complex immunological landscapes that nurture the growth of these malignancies. The knowledge gained from these investigations is being used to identify novel therapeutic targets and therapies for patients with early-stage, yet deadly thoracic malignancies.

Research Interests

Molecularly-targeted cancer therapies
Prognostic assays for early stage lung cancer
Inflammation in lung tumorigenesis

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 76
  1. Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.
    Sofia Diana Merajver, Aaron M Udager, Angel Qin, Kiran Lagisetty, Liwei Bao, Xu Cheng, Hamadi Madhi, Laura Goo, Varun Kathawate, Peter Ulintz, Albert Liu, Habib Serhan, Vishal Navani, John L. Jefferies, Muhammad Sajawal Ali, Michael Monument, Johannes Ruediger Kratz, Amber Smith, Matthew Soellner, Nathan Merrill| | UCSF Research Profile
  2. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, Rotow JK, Chakrabarti T, Kerr DL, Aredo JV, Bacaltos B, Gee M, Tan L, Jones KD, Devine WP, Doebele RC, Aisner DL, Patil T, Schenk EL, Bivona TG, Riess JW, Coleman M, Kratz JR, Jablons DM| | PubMed
  3. A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
    NIHR Global Health Research Unit on Global Surgery, STARSurg Collaborative| | PubMed
  4. Trans-Sternal Multilevel Corpectomy for Cervicothoracic Renal Cell Metastasis: 2-Dimensional Operative Video.
    Tawil ME, Chryssikos T, Sorour O, Ambati VS, Jamieson A, Theologis AA, Kratz J, Mummaneni PV| | PubMed
  5. Quantitative Polymerase Chain Reaction and Precision Medicine.
    Joel L. Ramirez, Johannes R. Kratz| | UCSF Research Profile
  6. Treatments for dengue: a Global Dengue Alliance to address unmet needs.
    Dengue Alliance. Electronic address: [email protected], Dengue Alliance| | PubMed
  7. PET Standardized Uptake Value May Influence Surgical Planning for Clinical Stage IA Non-Small Cell Lung Cancer.
    Murillo AD, Kratz JR| | PubMed
  8. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer.
    Jacqueline V. Aredo, Anatoly Urisman, Matthew A. Gubens, Claire Mulvey, Greg M. Allen, Julia K. Rotow, Daniel Lucas Kerr, Turja Chakrabarti, Bianca Bacaltos, Megan Gee, Kirk Jones, Dara L. Aisner, Tejas Patil, Erin Lynn Schenk, Trever G. Bivona, Jonathan W. Riess, Melissa Coleman, Johannes Ruediger Kratz, David Jablons, Collin M. Blakely| | UCSF Research Profile
  9. Transcriptional space-time mapping identifies concerted immune and stromal cell patterns and gene programs in wound healing and cancer.
    Hu KH, Kuhn NF, Courau T, Tsui J, Samad B, Ha P, Kratz JR, Combes AJ, Krummel MF| | PubMed
  10. 287 Genomic and Immunologic Characterization of Lung Adenocarcinoma in Never Smokers vs. Smokers.
    P. Jonathan Li, Jessica Tsui, Vivianne W. Ding, Alexis J. Combes, Matthew F. Krummel, David M. Jablons, Johannes R. Kratz| | UCSF Research Profile
  11. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas.
    Woodard GA, Ding V, Cho C, Brand NR, Kratz JR, Jones KD, Jablons DM| | PubMed
  12. SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants.
    Hysenaj L, Little S, Kulhanek K, Magnen M, Bahl K, Gbenedio OM, Prinz M, Rodriguez L, Andersen C, Rao AA, Shen A, Lone JC, Lupin-Jimenez LC, Bonser LR, Serwas NK, Mick E, Khalid MM, Taha TY, Kumar R, Li JZ, Ding VW, Matsumoto S, Maishan M, Sreekumar B, Simoneau C, Nazarenko I, Tomlinson MG, Khan K, von Gottberg A, Sigal A, Looney MR, Fragiadakis GK, Jablons DM, Langelier CR, Matthay M, Krummel M, Erle DJ, Combes AJ, Sil A, Ott M, Kratz JR, Roose JP| | PubMed
  13. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.
    Fotopoulou C, Khan T, Bracinik J, Glasbey J, Abu-Rustum N, Chiva L, Fagotti A, Fujiwara K, Ghebre R, Gutelkin M, Konney TO, Ng J, Pareja R, Kottayasamy Seenivasagam R, Sehouli J, Surappa STS, Bhangu A, Leung E, Sundar S, CovidSurg Gynecological Cancer Collaborators| | PubMed
  14. Discovering dominant tumor immune archetypes in a pan-cancer census.
    Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF| | PubMed
  15. Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
    Kratz JR, Li JZ, Tsui J, Lee JC, Ding VW, Rao AA, Mann MJ, Chan V, Combes AJ, Krummel MF, Jablons DM| | PubMed
  16. Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic.
    STARSurg Collaborative and COVIDSurg Collaborative| | PubMed
  17. Perioperative Lung Resection Outcomes After Implementation of a Multidisciplinary, Evidence-based Thoracic ERAS Program.
    Haro GJ, Sheu B, Marcus SG, Sarin A, Campbell L, Jablons DM, Kratz JR| | PubMed
  18. Multiomic Characterization of Stage I Lung Adenocarcinoma Reveals Distinct Genetic and Immunologic Features of Recurrent Disease.
    Jack Z. Li, Vivianne W. Ding, David M. Jablons, Johannes R. Kratz| | UCSF Research Profile
  19. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
    COVIDSurg Collaborative| | PubMed
  20. P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results.
    C. Blakely, A. Urisman, D. Kerr, W. Wu, B. Bacaltos, J. Rotow, M. Gubens, K. Jones, T. Bivona, S. Joo, J. Riess, D. Aisner, R. Doebele, T. Patil, E. Schenk, J. Kratz, D. Jablons| | UCSF Research Profile
  21. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
    COVIDSurg Collaborative, GlobalSurg Collaborative| | PubMed
  22. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    Gupta AR, Woodard GA, Jablons DM, Mann MJ, Kratz JR| | PubMed
  23. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
    COVIDSurg Collaborative, GlobalSurg Collaborative| | PubMed
  24. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Woodard GA, Kratz JR, Haro G, Gubens MA, Blakely CM, Jones KD, Mann MJ, Jablons DM| | PubMed
  25. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator.
    Hysenaj L, Little S, Kulhanek K, Gbenedio OM, Rodriguez L, Shen A, Lone JC, Lupin-Jimenez LC, Bonser LR, Serwas NK, Bahl K, Mick E, Li JZ, Ding VW, Matsumoto S, Maishan M, Simoneau C, Fragiadakis G, Jablons DM, Langelier CR, Matthay M, Ott M, Krummel M, Combes AJ, Sil A, Erle DJ, Kratz JR, Roose JP| | PubMed
  26. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity.
    Woodard GA, Fels Elliott DR, Yap A, Haro GJ, Kratz JR, Mann MJ, Jones KD, Jablons DM| | PubMed
  27. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
    COVIDSurg Collaborative, GlobalSurg Collaborative| | PubMed
  28. Bioinformatic Approaches to Validation and Functional Analysis of 3D Lung Cancer Models.
    Li PJ, Roose JP, Jablons DM, Kratz JR| | PubMed
  29. Commentary: Cardiothoracic surgery training: Global challenges without universal solutions.
    Kratz JR, Nguyen TC| | PubMed
  30. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy.
    G. Woodard, J. Kratz, G. Haro, M. Gubens, C. Blakely, K. Jones, M. Mann, D. Jablons| | UCSF Research Profile
  31. Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.
    Glasbey JC, Nepogodiev D, Simoes JFF, Omar O, Li E, Venn ML, Abou Chaar MK, Capizzi V, Chaudhry D, Desai A, Edwards JG, Evans JP, Fiore M, Videria JF, Ford SJ, Ganly I, Griffiths EA, Gujjuri RR, Kolias AG, Kaafarani HMA, Minaya-Bravo A, McKay SC, Mohan HM, Roberts KJ, San Miguel-Méndez C, Pockney P, Shaw R, Smart NJ, Stewart GD, Sundar Mrcog S, Vidya R, Bhangu AA, COVIDSurg Collaborative| | PubMed
  32. Delaying surgery for patients with a previous SARS-CoV-2 infection.
    COVIDSurg Collaborative| | PubMed
  33. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
    Maynard A, McCoach CE, Rotow JK, Harris L, Haderk F, Kerr DL, Yu EA, Schenk EL, Tan W, Zee A, Tan M, Gui P, Lea T, Wu W, Urisman A, Jones K, Sit R, Kolli PK, Seeley E, Gesthalter Y, Le DD, Yamauchi KA, Naeger DM, Bandyopadhyay S, Shah K, Cech L, Thomas NJ, Gupta A, Gonzalez M, Do H, Tan L, Bacaltos B, Gomez-Sjoberg R, Gubens M, Jahan T, Kratz JR, Jablons D, Neff N, Doebele RC, Weissman J, Blakely CM, Darmanis S, Bivona TG| | PubMed
  34. Pulmonary Embolus of Benign Liver Tissue Following Partial Hepatectomy.
    Calixto-Hope G. Lucas, Johannes R. Kratz, Anatoly Urisman| | UCSF Research Profile
  35. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.
    Haro GJ, Sheu B, Cook NR, Woodard GA, Mann MJ, Kratz JR| | PubMed
  36. Esophagectomy Outcomes after Implementation of an Enhanced Recovery after Surgery Program.
    Greg J. Haro, Fang Yu Sheu, Stanley J. Rogers, David M. Jablons, Johannes R. Kratz| | UCSF Research Profile
  37. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC.
    G. Woodard, V. Ding, I. Kim, K. Jones, G. Chavez, G. Haro, J. Kratz, M. Mann, J. Rotow, C. Blakely, D. Jablons| | UCSF Research Profile
  38. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer.
    J. Rotow, A. Urisman, C. Mccoach, T. Jahan, T. Bivona, K. Jones, A. Gupta, H. Do, J. Riess, D. Aisner, R. Doebele, D. Jablons, J. Kratz, C. Blakely| | UCSF Research Profile
  39. Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.
    Jiang L, Tolani B, Yeh CC, Fan Y, Reza JA, Horvai AE, Xia E, Kratz JR, Jablons DM, Mann MJ| | PubMed
  40. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    Kratz JR, Haro GJ, Cook NR, He J, Van Den Eeden SK, Woodard GA, Gubens MA, Jahan TM, Jones KD, Kim IJ, He B, Jablons DM, Mann MJ| | PubMed
  41. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    Lancaster EM, Jablons D, Kratz JR| | PubMed
  42. Quantitative Polymerase Chain Reaction for Companion Diagnostics and Precision Medicine Application.
    Joel L Ramirez, Johannes R Kratz| | UCSF Research Profile
  43. Central Airway Obstruction Due to Tracheal Glomus Tumor.
    Haro GJ, Seeley EJ, Jablons DM, Kratz JR| | PubMed
  44. Giant right coronary artery aneurysm presenting as cardiac tamponade.
    Ramirez JL, Kratz JR, Wieselthaler GM| | PubMed
  45. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy.
    G. Woodard, S. Wang, J. Kratz, G. Haro, M. Gubens, C. Blakely, T. Jahan, K. Jones, M. Mann, D. Jablons| | UCSF Research Profile
  46. P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    G. Haro, J. Kratz, N. Cook, J. He, S. Van Den Eeden, G. Woodard, M. Gubens, T. Jahan, K. Jones, I. Kim, B. He, D. Jablons, M. Mann| | UCSF Research Profile
  47. Propensity Matched Analysis of Perioperative Outcomes in Robotic-Assisted Thoracic Surgery, Video Assisted Thoracic Surgery, and Open Lung Resections.
    Greg J. Haro, Johannes R. Kratz, David M. Jablons, Michael J. Mann, Jasleen Kukreja| | UCSF Research Profile
  48. Intraoperative identification and treatment of a giant right coronary artery aneurysm.
    Ramirez J, Wieselthaler G, Kratz J| | PubMed
  49. Surgical Management of Pulmonary Mucormycosis in Third-Trimester Pregnancy.
    Ramirez JL, Urisman A, Kukreja J, Kratz JR| | PubMed
  50. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
    Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM| | PubMed
  51. Management of Lung Cancer Invading the Superior Sulcus.
    Kratz JR, Woodard G, Jablons DM| | PubMed
  52. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer.
    Gavitt Woodard, Jane Crockard, Clara Zoon-Besselink, Johannes Kratz, Matthew Gubens, Thierry Jahan, Collin Blakely, Kirk Jones, Michael Mann, David Jablons| | UCSF Research Profile
  53. P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: Staging.
    Johannes Kratz, Nancy Cook, Gavitt Woodard, Kirk Jones, Matthew Gubens, Thierry Jahan, Il-Jin Kim, Biao He, David Jablons, Michael Mann| | UCSF Research Profile
  54. High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation.
    Shah JA, Patel MS, Kratz JR, Markmann JF, Vagefi PA| | PubMed
  55. High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation.
    Shah JA, Patel MS, Kratz JR, Markmann JF, Vagefi PA| | PubMed
  56. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
    Hirata T, Zheng Q, Chen Z, Kinoshita H, Okamoto J, Kratz J, Li H, Lui N, Do H, Cheng T, Tseng HH, Koizumi K, Shimizu K, Zhou HM, Jablons D, He B| | PubMed
  57. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    Patel MS, Kohn R, Kratz JR, Shah JA, Markmann JF, Vagefi PA| | PubMed
  58. Prognostic and Predictive Biomarker Signatures.
    Johannes R. Kratz, David M. Jablons| | UCSF Research Profile
  59. The migrated liver transplantation candidate: insight into geographic disparities in liver distribution.
    Kohn R, Kratz JR, Markmann JF, Vagefi PA| | PubMed
  60. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.
    Kratz JR, Tham PT, Mulvihill MS, Ziaei F, Ray MR, Hurst JW, Segal MR, Berryman DM, Chu W, He B, Jablons DM, Mann MJ| | PubMed
  61. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.
    Kratz JR, Mann MJ, Jablons DM| | PubMed
  62. Prognostic assay in small, node-negative non-small cell lung cancer--reply.
    Mann MJ, Jablons DM, Kratz JR| | PubMed
  63. The role of stem cells in airway repair: implications for the origins of lung cancer.
    Mulvihill MS, Kratz JR, Pham P, Jablons DM, He B| | PubMed
  64. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.
    Kratz JR, Van den Eeden SK, He J, Jablons DM, Mann MJ| | PubMed
  65. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
    Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, Mao JH, Kang HC, Jablons D, Kim IJ| | PubMed
  66. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
    Kratz JR, He J, Van Den Eeden SK, Zhu ZH, Gao W, Pham PT, Mulvihill MS, Ziaei F, Zhang H, Su B, Zhi X, Quesenberry CP, Habel LA, Deng Q, Wang Z, Zhou J, Li H, Huang MC, Yeh CC, Segal MR, Ray MR, Jones KD, Raz DJ, Xu Z, Jahan TM, Berryman D, He B, Mann MJ, Jablons DM| | PubMed
  67. IL11 is prognostic of survival in lung adenocarcinoma.
    Johannes R. Kratz, Patrick T. Pham, Michael S. Mulvihill, M. Roshni Ray, Michael J. Mann, David M. Jablons| | UCSF Research Profile
  68. Child neurology: Brachial plexus birth injury: what every neurologist needs to know.
    Pham CB, Kratz JR, Jelin AC, Gelfand AA| | PubMed
  69. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.
    Okamoto J, Kratz JR, Hirata T, Mikami I, Raz D, Segal M, Chen Z, Zhou HM, Pham P, Li H, Yagui-Beltran A, Beltran A, Ray MR, Koizumi K, Shimizu K, Jablons D, He B| | PubMed
  70. Cancer stem cells in lung tumorigenesis.
    Kratz JR, Yagui-Beltrán A, Jablons DM| | PubMed
  71. Genomic prognostic models in early-stage lung cancer.
    Kratz JR, Jablons DM| | PubMed
  72. Anal canal duplication associated with presacral cyst.
    Kratz JR, Deshpande V, Ryan DP, Goldstein AM| | PubMed
  73. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2.
    Parmar KM, Larman HB, Dai G, Zhang Y, Wang ET, Moorthy SN, Kratz JR, Lin Z, Jain MK, Gimbrone MA, García-Cardeña G| | PubMed
  74. Fluid Mechanical Forces as Extrinsic Modifiers of Endothelial Function.
    Johannes Kratz, Kush Parmar, Sripriya Natarajan, Guillermo García-Cardeña| | UCSF Research Profile
  75. Clinical pulmonary autograft valves: pathologic evidence of adaptive remodeling in the aortic site.
    Rabkin-Aikawa E, Aikawa M, Farber M, Kratz JR, Garcia-Cardena G, Kouchoukos NT, Mitchell MB, Jonas RA, Schoen FJ| | PubMed
  76. Catalysis of peptide dissociation from class II MHC-peptide complexes.
    Schmitt L, Kratz JR, Davis MM, McConnell HM| | PubMed